Engineering nanotheranostic strategies for liver cancer

Figure 2 RGD-modified nanoparticles for targeted hepatocellular carcinoma therapy. A: Illustration of RGD-PDA-PHBV-PTX-NPs and targeted therapy; B: Specific targeting of RGD-modified PDA-PHBV-PTX-NPs for liver cancer cells; C: Distribution of various NPs in tumors in a HepG2 xenograft tumor model; D: Bio-distribution of NPs in major organs. Citation: Wu M, Zhong C, Zhang Q, Wang L, Wang L, Liu Y, Zhang X, Zhao X. pH-responsive delivery vehicle based on RGD-modified polydopamine-paclitaxel-loaded poly (3-hydroxybutyrate-co-3-hydroxyvalerate) nanoparticles for targeted therapy in hepatocellular carcinoma. J Nanobiotechnology 2021; 19: 39. Copyright ^© The Authors 2021. Published by BioMed Central Ltd.